Bevacizumab

Evidence Level: L5

Predicted Indications: 10

Bevacizumab

Pharmacist Assessment Report

Bevacizumab: Anti-VEGF-A monoclonal antibody → epiglottis neoplasm

One-Sentence Summary

Bevacizumab is a monoclonal antibody that blocks VEGF-A, a driver of tumour blood vessel growth, and it is marketed in India. The TxGNN model predicts it may be effective for epiglottis neoplasm, with a score of 0.9990. At present there are no clinical trials and no publications for this specific disease, so the support is model prediction only.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	epiglottis neoplasm
TxGNN Prediction Score	0.9990
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the data compiled for this report. Based on general knowledge, bevacizumab binds VEGF-A and limits the growth of new blood vessels that tumours depend on.

Epiglottis neoplasms arise in the head and neck region. Head and neck tumours are often rich in blood vessels, so blocking VEGF is a plausible approach. This reasoning is speculative here. No study in the compiled data tests bevacizumab in epiglottis tumours, and the prediction score is the only support.

Clinical Trial Evidence

Currently no related clinical trials registered for epiglottis neoplasm.

Literature Evidence

Currently no related literature available for epiglottis neoplasm.

India Market Information

The licence list may be partial. The licences below are a selection of the 20 valid single-ingredient registrations; no indication text is recorded for them.

Authorization Number	Product Name	Dosage Form	Approved Indication
13400	Avastimab 400mg Injection	Vial of 16 ml, injection	Not recorded
13987	Avastimab 100mg Injection	Vial of 4 ml, injection	Not recorded
110852	Ivzumab 400 Solution for Injection	Vial of 16 ml, solution for injection	Not recorded
116540	Krabeva 100mg Injection	Vial of 4 ml, injection	Not recorded
233880	Versavo 400 Solution for Infusion	Vial of 16 ml, solution for infusion	Not recorded

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (anti-VEGF monoclonal antibody)
Myelosuppression Risk	Low as a single agent; please refer to the package insert warnings and precautions
Emetogenicity Classification	Low
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: 22 interactions were identified in the data compiled for this report. The main ones rated Major are deferiprone, samarium (153Sm) lexidronam, panitumumab, sunitinib and thalidomide. Others are rated Moderate, including bisphosphonates (alendronic, risedronic, etidronic, pamidronic, ibandronate and tiludronic acids), filgrastim, pegfilgrastim, sargramostim, palifermin, idelalisib, romosozumab, radium Ra 223 dichloride, strontium chloride Sr-89 and sodium phosphate P32.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is very high (0.9990), but no trial or publication studies bevacizumab in epiglottis neoplasm. Evidence is therefore at L5 (model prediction only).

To proceed, the following is needed:

Search for clinical or preclinical data on bevacizumab in laryngeal and epiglottic tumours
Detailed mechanism-of-action data
Package insert warnings and contraindications from the Indian licence holders
A safety review of the major drug interactions, especially with sunitinib, panitumumab and thalidomide
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.